Press releases

Month Year

Email alerts

Aug 27, 2012

Five-Year Analysis of Pivotal REVERSE Trial Demonstrates Long-Term Clinical Benefits of Medtronic CRT-D Therapy in Mild Heart Failure Patients

Low Mortality and Heart Failure Hospitalization Sustained at 5-Years Post Implant with Medtronic CRT-D Devices

MUNICH, GERMANY – August 27, 2012 – Medtronic, Inc. (NYSE: MDT) today announced findings from a new clinical analysis of the pivotal REVERSE (Resynchronization Reverse Remodeling in Systolic...
Aug 24, 2012

Medtronic Receives FDA Approval, CE Mark for Arctic Front Advance™ Cardiac Cryoballoon to Treat Atrial Fibrillation

Next-Generation Technology Reinforces Safety and Efficacy While Improving Procedure Efficiency

MINNEAPOLIS – Aug. 24, 2012 – Medtronic, Inc. (NYSE:MDT) today announced that its Arctic Front Advance™ Cardiac Cryoballoon has received both U.S. Food and Drug Administration (FDA) approval...
Aug 23, 2012

Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2013

MINNEAPOLIS - August 23, 2012 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.26 per share of the company's common stock. The quarterly dividend...
Aug 21, 2012

Medtronic Reports First Quarter Earnings

Revenue of $4.0 Billion Grew 5% on a Constant Currency Basis; 2% as Reported

MINNEAPOLIS - August 21, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2013, which ended July 27, 2012. The Company reported worldwide...
Jun 21, 2012

Medtronic Stent Graft Chosen by U.S. FDA for Innovative Program

Regulatory Agency Selects Investigational Medical Device for Endovascular Treatment of Thoracic Aortic Aneurysms Involving Branch Vessel for Early Feasibility Pilot Program

MINNEAPOLIS -- June 21, 2012 -- The U.S. Food and Drug Administration (FDA) recently selected a stent graft being developed by Medtronic, Inc. (NYSE: MDT) for an early feasibility pilot program...

Show per page